GeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 1,266 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,266 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $159.28, for a total value of $201,648.48. Following the transaction, the chief financial officer directly owned 5,389 shares of the company’s stock, valued at approximately $858,359.92. This trade represents a 19.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, October 29th, Kevin Feeley sold 388 shares of GeneDx stock. The shares were sold at an average price of $136.54, for a total value of $52,977.52.
• On Tuesday, September 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $121.47, for a total value of $452,840.16.

GeneDx Stock Performance

WGS traded down $3.20 during trading hours on Thursday, hitting $155.37. The stock had a trading volume of 273,005 shares, compared to its average volume of 886,294. GeneDx Holdings Corp. has a 1 year low of $55.17 and a 1 year high of $170.87. The company’s fifty day simple moving average is $137.83 and its 200 day simple moving average is $112.69. The stock has a market cap of $4.49 billion, a PE ratio of 1,726.33 and a beta of 1.99. The company has a quick ratio of 2.59, a current ratio of 2.71 and a debt-to-equity ratio of 0.18.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.21. The firm had revenue of $116.74 million during the quarter, compared to analyst estimates of $104.33 million. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. Equities analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

A number of institutional investors have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp raised its holdings in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after acquiring an additional 186 shares in the last quarter. Quarry LP increased its position in shares of GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after purchasing an additional 209 shares during the last quarter. US Bancorp DE increased its position in shares of GeneDx by 3,223.5% in the first quarter. US Bancorp DE now owns 565 shares of the company’s stock worth $50,000 after purchasing an additional 548 shares during the last quarter. Gordian Capital Singapore Pte Ltd bought a new stake in GeneDx during the third quarter valued at approximately $65,000. Finally, AlphaQuest LLC lifted its position in GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock valued at $70,000 after purchasing an additional 594 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on WGS shares. Wall Street Zen lowered shares of GeneDx from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Piper Sandler raised their price target on GeneDx from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, September 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, October 8th. BTIG Research increased their price objective on GeneDx from $140.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Wells Fargo & Company lifted their target price on GeneDx from $95.00 to $140.00 and gave the company an “equal weight” rating in a report on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $129.22.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.